dipicolinic acid | CAS:499-83-2

We serve dipicolinic acid CAS:499-83-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
dipicolinic acid

Chemical Name:dipicolinic acid
CAS.NO:499-83-2
Synonyms:pyridine-2,6-dicarboxylic acid;
Molecular Formula:C7H5NO4
Molecular Weight:167.11900
 
Physical and Chemical Properties:
Density:1.551;
Melting point:248-250oC;
Boiling point:463.7oC;
Flash point:188oC;
 
Specification:
Appearance:Off-white to white crystalline powder
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Hair dyes intermediate
 



Contact us for information like dipicolinic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pyridine-2,6-dicarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,dipicolinic acid Use and application,dipicolinic acid technical grade,usp/ep/jp grade.


Related News: Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.Pemetrexed acid manufacturer Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.4-Amino-3,5-dichloropyridine supplier Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.1-Bromo-2,4,5-trifluorobenzene vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.